Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nexalin Technology, Inc. - Common Stock (NQ:NXL)

0.4895 -0.0405 (-7.64%)
Streaming Delayed Price Updated: 12:04 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 713,731
Open 0.5100
Bid (Size) 0.4775 (900)
Ask (Size) 0.4895 (200)
Prev. Close 0.5300
Today's Range 0.4650 - 0.5688
52wk Range 0.3050 - 2.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
Discover the top movers in Friday's pre-market session. ↗
Via Chartmill

Performance

YTD
-16.0%
-16.0%
1 Month
+28.7%
+28.7%
3 Month
+10.9%
+10.9%
6 Month
-50.3%
-50.3%
1 Year
-61.2%
-61.2%

More News

Read More
News headline image
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
RedChip's Biotech Investor Conference Replays Now Available
Via ACCESS Newswire
News headline image
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference
Via ACCESS Newswire
News headline image
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Unusual volume stocks in Friday's session ↗
Via Chartmill
News headline image
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
From Nexalin Technology, Inc.
Via GlobeNewswire
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Receives Nasdaq Listing Status Notification
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
From Nexalin Technology, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Nexalin Technology, Inc. - Common Stock publicly traded?
Yes, Nexalin Technology, Inc. - Common Stock is publicly traded.
What exchange does Nexalin Technology, Inc. - Common Stock trade on?
Nexalin Technology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nexalin Technology, Inc. - Common Stock?
The ticker symbol for Nexalin Technology, Inc. - Common Stock is NXL on the Nasdaq Stock Market
What is the current price of Nexalin Technology, Inc. - Common Stock?
The current price of Nexalin Technology, Inc. - Common Stock is 0.4895
When was Nexalin Technology, Inc. - Common Stock last traded?
The last trade of Nexalin Technology, Inc. - Common Stock was at 06/04/26 12:04 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.